BCL6 in T cells promotes type 1 diabetes by redirecting fates of insulin-autoreactive B lymphocytes
Landon M Clark, Jack C McAninch, Dudley H McNitt, Marguerite L Padgett, Tyler W Jenkins, Lindsay E Bass, Casey M Nichols, Jeffrey C Rathmell, Rachel H Bonami · 2026
Read BCL6 in T cells promotes type 1 diabetes by redirecting fates of insulin-autoreactive B lymphocytes by Landon M Clark, Jack C McAninch, Dudley H McNitt, Marguerite L Padgett, Tyler W Jenkins, Lindsay E Bass, Casey M Nichols, Jeffrey C Rathmell, Rachel H Bonami (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13267562.txt.
Description
In type 1 diabetes, the immune system destroys insulin-making cells, and most therapies aim bluntly at T cells. Landon Clark and co-authors showed in 2026 that one T cell protein, BCL6, quietly steers B cells toward attacking insulin.
Mice whose T cells lacked BCL6 stayed free of diabetes, even though insulin-targeting B cells still circulated. Those B cells activated and multiplied less, and fewer gathered in the odd, atypical states seen near the pancreas. Helper T cells without BCL6 also fired less. The work names BCL6 as a selective drug target that might calm the anti-insulin attack without broad immune suppression.
Catalog record
| CREATOR | Landon M Clark, Jack C McAninch, Dudley H McNitt, Marguerite L Padgett, Tyler W Jenkins, Lindsay E Bass, Casey M Nichols, Jeffrey C Rathmell, Rachel H Bonami |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |